Skip to main content

HyperGenomics Signs Contract for Provision of First Revenues

NEW YORK (GenomeWeb News) – HyperGenomics has signed a contract with an undisclosed partner that is expected to provide the firm with its first revenues, its parent firm VolitionRx said today.

The deal calls for Singapore-based VolitionRx to develop epigenetic profiling signatures from blood and makes HyperGenomics eligible for payments of up to a total of US$55,000 if milestones are met during the next eight months.

HyperGenomics is partnering with Biomedicum Genomics in Finland for the sequencing and bioinformatics part of the workflow.

HyperGenomics' technology is based on cutting up a genome at certain spots and then sequencing it. The company's tests are planned for use as a second line upon the diagnosis of cancer, or other disease, in order to determine the specific subtype and decide the most appropriate therapy, it said.

Filed under

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.